gMendel and Netcetera develop the Phivea® platform

Artificial intelligence helps diagnose rare genetic disorders faster, more reliably, and more affordably

Artificial intelligence (AI) can make a big difference in healthcare. In a major, forward-looking project, Netcetera and Mendel® are demonstrating the advances AI can bring. In partnership, the companies have developed the Phivea® platform. The goal of it is to improve the diagnosis of genetic disorders and subsequent disease management.

DNA analysis is a complex, lengthy, and in some cases unreliable process. gMendel® is a medical technology start-up that aims to make a lasting positive impact on the analysis of genetic disorders: diagnosing genetic disorders faster and more cost-effectively. Together with Netcetera and the University of Copenhagen, they have developed the Phivea® platform, which makes genetic analysis safer, more reliable, and more affordable. By combining genomics, AI and blockchain, gMendel®Test provides a shorter, safer, and more economical path to accurate diagnosis and potential treatment, ensuring the highest security and patient data encryption.

Leveraging machine learning to improve and speed up diagnosis

Phivea® was created by bringing together genomics, artificial intelligence, and blockchain. DNA sequences from up to 96 different individuals are linked together using barcodes and scanned in the Oxford Nanopore Sequencer. To analyze these different gene sequences, Netcetera has developed the machine learning algorithm Torchlex. Torchlex reduces computational complexity and significantly increases the speed of analysis while maintaining the same quality and accuracy compared to competing methods. This method allows to significantly reduce the cost of analysis per gene sample.

The personal experiences of the two initiators and founders of gMendel®, Chris Kyriakidis and Zoran Velkoski, were decisive for the development of this method. Chris Kyriakidis' daughter was diagnosed with selective mutism. After making remarkable progress, she is now taking part in all learning and social activities at her school. Zoran Velkoski's school friend was diagnosed with a rare type of cancer that could only be determined by DNA sequencing. This technology has been available for a long time. However, it was unfortunately very expensive and therefore not affordable for many people. The two entrepreneurs set out to make DNA sequencing routine clinical practice by using smart technology to enable early, accurate and affordable diagnosis of genetic disorders. The aim is to transform the diagnosis of genetic disorders for better disease management.

More stories

On this topic